Silexion Therapeutics to participate in September 2026 industry conferences
Silexion Therapeutics announced management will participate in September 2026 Industry and Investor Conferences. The company is a clinical-stage biotechnology focused on RNA interference (RNAi) therapies for KRAS-driven cancers.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.